The target is to produce RPE cells and neurons derived from other iPS cells. The company will invest 3.6 billion Yen in their research laboratory in Suita City, Osaka Prefecture, were the new 3000 m2 CPC will be constructed and become operational in FY 2017.

Dainippon Sumitomo Pharmaceuticals press release, February 21, 2017